Intelligent nanovesicle for remodeling tumor microenvironment and circulating tumor chemoimmunotherapy amplification
Open Access
- 16 May 2024
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-17
Abstract
Imperceptible examination and unideal treatment effect are still intractable difficulties for the clinical treatment of pancreatic ductal adenocarcinoma (PDAC). At present, despite 5-fluorouracil (5-FU), as a clinical first-line FOLFIRINOX chemo-drug, has achieved significant therapeutic effects. Nevertheless, these unavoidable factors such as low solubility, lack of biological specificity and easy to induce immunosuppressive surroundings formation, severely limit their treatment in PDAC. As an important source of energy for many tumor cells, tryptophan (Trp), is easily degraded to kynurenine (Kyn) by indolamine 2,3- dioxygenase 1 (IDO1), which activates the axis of Kyn-AHR to form special suppressive immune microenvironment that promotes tumor growth and metastasis. However, our research findings that 5-FU can induce effectively immunogenic cell death (ICD) to further treat tumor by activating immune systems, while the secretion of interferon-γ (IFN-γ) re-induce the Kyn-AHR axis activation, leading to poor treatment efficiency. Therefore, a metal matrix protease-2 (MMP-2) and endogenous GSH dual-responsive liposomal-based nanovesicle, co-loading with 5-FU (anti-cancer drug) and NLG919 (IDO1 inhibitor), was constructed (named as ENP919@5-FU). The multifunctional ENP919@5-FU can effectively reshape the tumor immunosuppression microenvironment to enhance the effect of chemoimmunotherapy, thereby effectively inhibiting cancer growth. Mechanistically, PDAC with high expression of MMP-2 will propel the as-prepared nanovesicle to dwell in tumor region via shedding PEG on the nanovesicle surface, effectively enhancing tumor uptake. Subsequently, the S-S bond containing nanovesicle was cut via high endogenous GSH, leading to the continued release of 5-FU and NLG919, thereby enabling circulating chemoimmunotherapy to effectively cause tumor ablation. Moreover, the combination of ENP919@5-FU and PD-L1 antibody (αPD-L1) showed a synergistic anti-tumor effect on the PDAC model with abdominal cavity metastasis. Collectively, ENP919@5-FU nanovesicle, as a PDAC treatment strategy, showed excellent antitumor efficacy by remodeling tumor microenvironment to circulate tumor chemoimmunotherapy amplification, which has promising potential in a precision medicine approach.Keywords
Funding Information
- National Natural Science Foundation of China (82172737)
This publication has 44 references indexed in Scilit:
- Augmenting Immunogenic Cell Death and Alleviating Myeloid‐Derived Suppressor Cells by Sono‐Activatable Semiconducting Polymer Nanopartners for ImmunotherapyAdvanced Materials, 2023
- Tumor Therapy Strategies Based on Microenvironment‐Specific Responsive NanomaterialsAdvanced Healthcare Materials, 2023
- Nanovaccines with cell-derived components for cancer immunotherapyAdvanced Drug Delivery Reviews, 2022
- Regulating Glucose Metabolism with Prodrug Nanoparticles for Promoting Photoimmunotherapy of Pancreatic CancerAdvanced Science, 2021
- Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune ToleranceCellular and Molecular Gastroenterology and Hepatology, 2021
- IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor ProgressionCell, 2020
- The tumor microenvironmentCurrent Biology, 2020
- Dilemma and Challenge of Immunotherapy for Pancreatic CancerDigestive Diseases and Sciences, 2020
- The role of AhR in transcriptional regulation of immune cell development and functionBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2020
- PD-1/PD-L1 and immunotherapy for pancreatic cancerCancer Letters, 2017